Mogrify and Sangamo in license agreement for ‘off-the-shelf’ CAR-Treg 23-Apr-2020 By Ben Hargreaves Sangamo plans to utilize Mogrify’s cell conversion technology to develop CAR-Treg cell therapies.
TxCell CEO says acquisition by Sangamo a ‘perfect fit’ 25-Jul-2018 By Ben Hargreaves TxCell confirmed that it has accepted a €72m offer from Sangamo in a deal that will be completed by the end of the year.